{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:40:02Z","timestamp":1763430002323,"version":"3.40.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20290"],"award-info":[{"award-number":["U22A20290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01878-0","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T17:31:28Z","timestamp":1746379888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Mengya","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangchao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinshui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiewen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"issue":"1","key":"1878_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40\u20137.","journal-title":"Blood"},{"issue":"22","key":"1878_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575\u201382.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1878_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2021013998","volume":"139","author":"EA Hawkes","year":"2022","unstructured":"Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139(6):822\u201334.","journal-title":"Blood"},{"issue":"1","key":"1878_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S. Transformed follicular lymphoma. Ann Hematol. 2018;97(1):17\u201329.","journal-title":"Ann Hematol"},{"key":"1878_CR5","doi-asserted-by":"publisher","first-page":"204062071881669","DOI":"10.1177\/2040620718816698","volume":"10","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Ther Adv Hematol. 2019;10:2040620718816698.","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"1878_CR6","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","volume":"25","author":"JK Lue","year":"2019","unstructured":"Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI, et al. Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin Cancer Res. 2019;25(17):5271\u201383.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1878_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11864-020-00761-9","volume":"21","author":"JC Cogan","year":"2020","unstructured":"Cogan JC, Liu Y, Amengual JE. Hypomethylating agents in lymphoma. Curr Treat Options Oncol. 2020;21(8):61.","journal-title":"Curr Treat Options Oncol"},{"key":"1878_CR8","doi-asserted-by":"publisher","first-page":"780118","DOI":"10.3389\/fonc.2021.780118","volume":"11","author":"M Zhong","year":"2021","unstructured":"Zhong M, Tan J, Pan G, Jiang Y, Zhou H, Lai Q, Chen Q, Fan L, Deng M, Xu B, et al. Preclinical evaluation of the HDAC inhibitor chidamide in transformed follicular lymphoma. Front Oncol. 2021;11:780118.","journal-title":"Front Oncol"},{"issue":"3","key":"1878_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nbt.1759","volume":"29","author":"M Bantscheff","year":"2011","unstructured":"Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M, Schlegl J, Abraham Y, Becher I, Bergamini G, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011;29(3):255\u201365.","journal-title":"Nat Biotechnol"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"101779","DOI":"10.1016\/j.tranon.2023.101779","volume":"39","author":"AP Havas","year":"2024","unstructured":"Havas AP, Tula-Sanchez AA, Steenhoek HM, Bhakta A, Wingfield T, Huntley MJ, Nofal AS, Ahmed T, Jaime-Frias R, Smith CL. Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome na\u00efve resistance to pan-HDACi in diffuse large B cell lymphoma. Transl Oncol. 2024;39:101779.","journal-title":"Transl Oncol"},{"issue":"3","key":"1878_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12033-010-9335-9","volume":"47","author":"R Macarr\u00f3n","year":"2011","unstructured":"Macarr\u00f3n R, Hertzberg RP. Design and implementation of high throughput screening assays. Mol Biotechnol. 2011;47(3):270\u201385.","journal-title":"Mol Biotechnol"},{"issue":"9","key":"1878_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.chembiol.2014.07.015","volume":"21","author":"WP Janzen","year":"2014","unstructured":"Janzen WP. Screening technologies for small molecule discovery: the state of the art. Chem Biol. 2014;21(9):1162\u201370.","journal-title":"Chem Biol"},{"issue":"1","key":"1878_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi D, Tabb\u00f2 F, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130\u201340.","journal-title":"Cell Rep"},{"issue":"9","key":"1878_CR14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604\u201311.","journal-title":"Blood"},{"issue":"8","key":"1878_CR15","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","volume":"82","author":"F Lo Coco","year":"1993","unstructured":"Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82(8):2289\u201395.","journal-title":"Blood"},{"issue":"4","key":"1878_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JHJM, Baars JW, Raemaekers J, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25(4):390\u20138.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1878_CR17","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O\u2019Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1878_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","volume":"24","author":"OA O'Connor","year":"2006","unstructured":"O\u2019Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166\u201373.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1878_CR19","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdn031","volume":"19","author":"M Crump","year":"2008","unstructured":"Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964\u20139.","journal-title":"Ann Oncol"},{"key":"1878_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s12864-015-2093-0","volume":"16","author":"R Cao","year":"2015","unstructured":"Cao R, Cheng J. Deciphering the association between gene function and spatial gene-gene interactions in 3D human genome conformation. BMC Genom. 2015;16:880.","journal-title":"BMC Genom"},{"issue":"3","key":"1878_CR21","doi-asserted-by":"publisher","first-page":"1554175","DOI":"10.1080\/2162402X.2018.1554175","volume":"8","author":"C Rossi","year":"2019","unstructured":"Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini D-M, Laurent C, Morin R, Lagarde J-M, et al. Boosting \u03b3\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology. 2019;8(3):1554175.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1878_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","volume":"15","author":"S Dalle","year":"2009","unstructured":"Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res. 2009;15(3):851\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1878_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.15797","volume":"185","author":"H Chiu","year":"2019","unstructured":"Chiu H, Trisal P, Bjorklund C, Carrancio S, Tora\u00f1o EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, et al. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019;185(2):240\u201353.","journal-title":"Br J Haematol"},{"issue":"38","key":"1878_CR24","doi-asserted-by":"publisher","first-page":"31983","DOI":"10.1074\/jbc.M112.374751","volume":"287","author":"M Winiarska","year":"2012","unstructured":"Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, et al. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. J Biol Chem. 2012;287(38):31983\u201393.","journal-title":"J Biol Chem"},{"issue":"1","key":"1878_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","volume":"12","author":"W Li","year":"2019","unstructured":"Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, Greipp PT, Elsawa SF, Sotomayor EM, Gupta M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1878_CR26","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7(10):3265\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1878_CR27","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3390\/biomedicines11061758","volume":"11","author":"S Nagel","year":"2023","unstructured":"Nagel S, Pommerenke C, Meyer C, Kaufmann M, MacLeod RAF. Chromosomal aberration t(14;17)(q32;q21) simultaneously activates HOXB5 and miR10a in triple-hit B-Cell lymphoma. Biomedicines. 2023;11(6):3145.","journal-title":"Biomedicines"},{"issue":"7","key":"1878_CR28","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3109\/10428194.2014.981172","volume":"56","author":"N Johnson-Farley","year":"2015","unstructured":"Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in \u201cdouble hit\u201d lymphoma cells. Leuk Lymphoma. 2015;56(7):2146\u201352.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1878_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00432-024-05939-4","volume":"150","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. J Cancer Res Clin Oncol. 2024;150(9):426.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1878_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ijc.2910390116","volume":"39","author":"KH Th'ng","year":"1987","unstructured":"Th\u2019ng KH, Garewal G, Kearney L, Rassool F, Melo JV, White H, Catovsky D, Foroni L, Luzzatto L, Goldman JM. Establishment and characterization of three new malignant lymphoid cell lines. Int J Cancer. 1987;39(1):89\u201393.","journal-title":"Int J Cancer"},{"issue":"2","key":"1878_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.37906","volume":"16","author":"M Zhong","year":"2020","unstructured":"Zhong M, Li N, Qiu X, Ye Y, Chen H, Hua J, Yin P, Zhuang G. TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer. Int J Biol Sci. 2020;16(2):272\u201383.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"1878_CR32","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.drudis.2020.07.024","volume":"25","author":"V Blay","year":"2020","unstructured":"Blay V, Tolani B, Ho SP, Arkin MR. High-Throughput Screening: today\u2019s biochemical and cell-based approaches. Drug Discov Today. 2020;25(10):1807\u201321.","journal-title":"Drug Discov Today"},{"issue":"13","key":"1878_CR33","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1073\/pnas.1337088100","volume":"100","author":"AA Borisy","year":"2003","unstructured":"Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A. 2003;100(13):7977\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1878_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/nchembio.689","volume":"7","author":"BG Small","year":"2011","unstructured":"Small BG, McColl BW, Allmendinger R, Pahle J, L\u00f3pez-Castej\u00f3n G, Rothwell NJ, Knowles J, Mendes P, Brough D, Kell DB. Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol. 2011;7(12):902\u20138.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1878_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","volume":"9","author":"Y Shi","year":"2002","unstructured":"Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459\u201370.","journal-title":"Mol Cell"},{"issue":"11","key":"1878_CR36","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1038\/cddis.2012.171","volume":"3","author":"A Perelman","year":"2012","unstructured":"Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis. 2012;3(11):e430.","journal-title":"Cell Death Dis"},{"issue":"8","key":"1878_CR37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli C, Skotheim JM, de Bruin RAM. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14(8):518\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"1878_CR38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/molecules27123714","volume":"27","author":"L Fan","year":"2022","unstructured":"Fan L, Peng C, Zhu X, Liang Y, Xu T, Xu P, Wu S. Dihydrotanshinone I enhances cell adhesion and inhibits cell migration in osteosarcoma U-2 OS Cells through CD44 and chemokine signaling. Molecules. 2022;27(12):418.","journal-title":"Molecules"},{"issue":"1","key":"1878_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25(1):104\u201313.","journal-title":"Cell Death Differ"},{"issue":"9","key":"1878_CR40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen K, Yang Q, Zha J, Deng M, Zhou Y, Fu G, Bi S, Feng L, Xu-Monette ZY, Chen XL, et al. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis. 2020;11(9):778.","journal-title":"Cell Death Dis"},{"issue":"7782","key":"1878_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"key":"1878_CR42","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai C-J, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"1878_CR43","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1878_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/10915818231178693","volume":"42","author":"Z Li","year":"2023","unstructured":"Li Z, Pan G, Zhong M, Zhang L, Yu X, Zha J, Xu B. High-throughput drug screen for potential combinations with venetoclax guides the treatment of transformed follicular lymphoma. Int J Toxicol. 2023;42(5):386\u2013406.","journal-title":"Int J Toxicol"},{"issue":"2","key":"1878_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"6","key":"1878_CR46","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/leu.2014.1","volume":"28","author":"SL Khaw","year":"2014","unstructured":"Khaw SL, M\u00e9rino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, Huang DCS. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28(6):1207\u201315.","journal-title":"Leukemia"},{"issue":"12","key":"1878_CR47","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121(12):2285\u20138.","journal-title":"Blood"},{"issue":"8","key":"1878_CR48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1878_CR49","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795\u2013804.","journal-title":"Leukemia"},{"issue":"6","key":"1878_CR50","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985\u201399.","journal-title":"Cell"},{"issue":"362","key":"1878_CR51","doi-asserted-by":"publisher","first-page":"ra12","DOI":"10.1126\/scisignal.2005654","volume":"8","author":"MP Walker","year":"2015","unstructured":"Walker MP, Stopford CM, Cederlund M, Fang F, Jahn C, Rabinowitz AD, Goldfarb D, Graham DM, Yan F, Deal AM, et al. FOXP1 potentiates Wnt\/\u03b2-catenin signaling in diffuse large B cell lymphoma. Sci Signal. 2015;8(362):ra12.","journal-title":"Sci Signal"},{"issue":"8","key":"1878_CR52","doi-asserted-by":"publisher","first-page":"e3186","DOI":"10.1002\/jgm.3186","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang P-Y, Yang Z-W, Ma F, Li F-X. TIMD4 exhibits regulatory capability on the proliferation and apoptosis of diffuse large B-cell lymphoma cells via the Wnt\/\u03b2-catenin pathway. J Gene Med. 2020;22(8):e3186.","journal-title":"J Gene Med"},{"issue":"1","key":"1878_CR53","doi-asserted-by":"publisher","first-page":"8602","DOI":"10.1038\/s41598-017-09239-5","volume":"7","author":"A Krishnankutty","year":"2017","unstructured":"Krishnankutty A, Kimura T, Saito T, Aoyagi K, Asada A, Takahashi S-I, Ando K, Ohara-Imaizumi M, Ishiguro K, Hisanaga S-I. In vivo regulation of glycogen synthase kinase 3\u03b2 activity in neurons and brains. Sci Rep. 2017;7(1):8602.","journal-title":"Sci Rep"},{"issue":"10","key":"1878_CR54","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5(10):1024\u201339.","journal-title":"Cancer Discov"},{"issue":"12","key":"1878_CR55","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-17-3107","volume":"78","author":"Q Wang","year":"2018","unstructured":"Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY, et al. Deptor is a novel target of Wnt\/\u03b2-catenin\/c-Myc and contributes to colorectal cancer cell growth. Cancer Res. 2018;78(12):3163\u201375.","journal-title":"Cancer Res"},{"issue":"4","key":"1878_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/embor.2012.12","volume":"13","author":"MV Hadjihannas","year":"2012","unstructured":"Hadjihannas MV, Bernkopf DB, Br\u00fcckner M, Behrens J. Cell cycle control of Wnt\/\u03b2-catenin signalling by conductin\/axin2 through CDC20. EMBO Rep. 2012;13(4):347\u201354.","journal-title":"EMBO Rep"},{"issue":"2","key":"1878_CR57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1006\/excr.1999.4677","volume":"253","author":"E Hulleman","year":"1999","unstructured":"Hulleman E, Bijvelt JJ, Verkleij AJ, Verrips CT, Boonstra J. Integrin signaling at the M\/G1 transition induces expression of cyclin E. Exp Cell Res. 1999;253(2):422\u201331.","journal-title":"Exp Cell Res"},{"issue":"5","key":"1878_CR58","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1042\/BST20120092","volume":"40","author":"M-K Yoon","year":"2012","unstructured":"Yoon M-K, Mitrea DM, Ou L, Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans. 2012;40(5):981\u20138.","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"1878_CR59","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):963.","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01878-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T19:02:37Z","timestamp":1746385357000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01878-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01878-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"type":"electronic","value":"1868-7083"}],"subject":[],"published":{"date-parts":[[2025,5,4]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments have been supervised and approved by the Laboratory Animal Ethics and Management Committee of Xiamen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"74"}}